New Kidney Drug Cuts Death Risk in Two-Year Trial

A breakthrough drug is giving new hope to patients with a progressive kidney disease that often leads to organ failure.

Vera Therapeutics announced Tuesday that Trutakna, which received accelerated FDA approval in July, successfully stabilized kidney function and reduced the risk of kidney-related death in patients with IgA nephropathy. The two-year Phase 3 trial results show the drug delivered on its promise to slow down this devastating autoimmune condition.

IgA nephropathy affects tens of thousands of Americans when immune antibodies build up in the kidneys, gradually destroying their ability to filter waste from the blood. Without effective treatment, many patients face complete kidney failure and a lifetime of dialysis or the need for a transplant.

The FDA granted Trutakna accelerated approval in July based on earlier data, allowing patients immediate access to the treatment. Now, with complete two-year results in hand, Vera plans to seek full FDA approval during the fourth quarter of this year.

The Ripple Effect

Beyond keeping kidneys functioning longer, Trutakna's success represents a major shift in how doctors can treat autoimmune kidney diseases. For years, patients had limited options to slow the progression of IgA nephropathy, watching helplessly as their kidney function declined.

The drug's ability to reduce complications means fewer emergency interventions, less time in hospitals, and more years of normal life for patients. Families won't have to plan around dialysis schedules or wait anxiously for organ transplants.

The pharmaceutical industry is taking notice too. Strong results in kidney disease trials often spark more investment and research into similar treatments, potentially accelerating the development of therapies for related conditions.

Full FDA approval would make Trutakna more widely available through insurance coverage and give doctors greater confidence in prescribing it as a first-line treatment. That means more patients could start the drug earlier in their disease progression, before significant kidney damage occurs.

For the thousands of people living with IgA nephropathy, this two-year data offers something precious: time and the chance to keep their kidneys working longer.